Vision Recovery Velocity, Momentum and Acceleration: Advanced Vitreoretinal Analytics as Measure of Treatment Efficacy for Neovascular Age-Related Macular Degeneration

Código QR

Vision Recovery Velocity, Momentum and Acceleration: Advanced Vitreoretinal Analytics as Measure of Treatment Efficacy for Neovascular Age-Related Macular Degeneration

David RP Almeida,1 Jessica Ruzicki,2 Kunyong Xu,3 Eric K Chin4 1Vitreoretinal Diseases & Surgery, Erie Retinal Surgery, Erie, PA, USA; 2Department of Ophthalmology, Queen’s University, Kingston, Ontario, Canada; 3Department of Ophthalmology and Visual Sciences, University of Arizon...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Almeida DRP, Ruzicki J, Xu K, Chin EK
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	vascular endothelial growth factor inhibitors neovascular age-related macular degeneration Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/ec208dda41e8487f98aeeb2120faae81
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Management of neovascular age-related macular degeneration: Taiwan expert consensus
por: Ling Yeung, et al.
Publicado: (2021)

Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
por: Yannuzzi NA, et al.
Publicado: (2019)

Treatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomes
por: Pedrosa AC, et al.
Publicado: (2016)

Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration
por: Balaratnasingam C, et al.
Publicado: (2015)

Neovascular age-related macular degeneration without drusen in the fellow eye: clinical spectrum and therapeutic outcome
por: Chung WH, et al.
Publicado: (2016)

A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK
por: Hykin P, et al.
Publicado: (2016)

Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration
por: Cheema MR, et al.
Publicado: (2021)

Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment
por: Pongsachareonnont P, et al.
Publicado: (2018)

Synthetic anti-angiogenic genomic therapeutics for treatment of neovascular age-related macular degeneration
por: Jing Wang, et al.
Publicado: (2021)

Patient Preferences Associated with Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
por: Bhagat D, et al.
Publicado: (2020)

Quantitative Comparison of the Vascular Structure of Macular Neovascularizations Between Swept-Source and Spectral-Domain Optical Coherence Tomography Angiography
por: Faatz H, et al.
Publicado: (2020)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
por: Nudleman E, et al.
Publicado: (2016)

The Anti-Inflammatory Effect of Hydrogen Gas Inhalation and Its Influence on Laser-Induced Choroidal Neovascularization in a Mouse Model of Neovascular Age-Related Macular Degeneration
por: I-Chia Liang, et al.
Publicado: (2021)

Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUSTM Study
por: Leys AM, et al.
Publicado: (2020)

Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date
por: Chen ER, et al.
Publicado: (2020)

Real-World Effectiveness, Treatment Pattern, and Safety of Ranibizumab in Korean Patients with Neovascular Age-Related Macular Degeneration: Subgroup Analyses from the LUMINOUS Study
por: Sagong M, et al.
Publicado: (2021)

Comparison of choroidal neovascularization secondary to white dot syndromes and age-related macular degeneration by using optical coherence tomography angiography
por: Wang JC, et al.
Publicado: (2018)

Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning
por: Miyamoto N, et al.
Publicado: (2017)

Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab
por: Nixon DR, et al.
Publicado: (2017)

Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
por: Khanani AM, et al.
Publicado: (2019)

Real-World Outcomes of Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration: A Large-Scale Postmarketing Surveillance in Korea
por: Ryu G, et al.
Publicado: (2021)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
por: Garweg JG
Publicado: (2019)

Incidence of Glaucoma or Ocular Hypertension After Repeated Anti-Vascular Endothelial Growth Factor Injections for Macular Degeneration
por: Wingard JB, et al.
Publicado: (2019)

Treatment Course of Patients with Exudative Age-Related Macular Degeneration Using Ocular Hypotensives
por: Modjtahedi BS, et al.
Publicado: (2020)

Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
por: Kabanarou SA, et al.
Publicado: (2017)

Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice
por: Andrea Montesel, et al.
Publicado: (2021)

To Peel or Not to Peel: Pars Plana Vitrectomy with Macular Membrane Peel in Eyes with Abnormalities of Vitreomacular Interface and Coexisting Dry Age-Related Macular Degeneration
por: Furashova O, et al.
Publicado: (2020)

Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration? A Prospective, Randomized, Pilot Study
por: Solomon SD, et al.
Publicado: (2021)

The Impact of Non-Ophthalmic Factors on Intravitreal Injections During the COVID-19 Lockdown
por: Ashrafzadeh S, et al.
Publicado: (2021)

Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update
por: Patel PJ, et al.
Publicado: (2017)

Acquired Vitelliform Macular Degeneration: Characteristics and Challenges of Managing Subretinal Fluid
por: Joseph Juliano, et al.
Publicado: (2021)

Choriocapillaris Vascular Density Changes: Healthy vs. Advanced Exudative Age-Related Macular Degeneration Previously Treated with Multiple Anti-VEGF Intravitreal Injections
por: Maria Cristina Savastano, et al.
Publicado: (2021)

Circulating monocytes and B-lymphocytes in neovascular age-related macular degeneration
por: Hector SM, et al.
Publicado: (2017)

Idiopathic polypoidal choroidal vasculopathy in Thai patients with clinical and angiographic choroidal neovascularization
por: Bhoomibunchoo C, et al.
Publicado: (2017)

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study
por: Chakraborty D, et al.
Publicado: (2021)

Visual Outcome and Treatment Frequency of Anti-VEGF Therapy Using the Treat-and-Extend and Treatment Cessation Regimen for Exudative Age-Related Macular Degeneration and Pachychoroid Neovasculopathy
por: Kinoshita T, et al.
Publicado: (2021)

Associations of ARMS2 and CFH Gene Polymorphisms with Neovascular Age-Related Macular Degeneration
por: Supanji S, et al.
Publicado: (2021)

The burden of neovascular age-related macular degeneration: a patient’s perspective
por: Spooner KL, et al.
Publicado: (2018)

One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement
por: Hirakata T, et al.
Publicado: (2016)

Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization
por: Tan CS, et al.
Publicado: (2017)